Dr. Paul C Turkeltaub, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 9112 Fall River Ln, Potomac, MD 20854 Phone: 301-983-0237 Fax: 240-353-1161 |
News Archive
Tuberculosis kills two million people each year and is once again gaining ground also in Sweden and other Western countries. Researchers at Linköping University in Sweden are now presenting new findings that show how the tubercle bacterium manages to survive inside the body's macrophage cells in order eventually to blow them up and spread their infection.
BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15.
Biota Holdings Limited today announced that Daiichi Sankyo has received approval to manufacture and market Inavir® in Japan. Inavir® is Daiichi Sankyo's brand of laninamivir octanoate and also previously known as CS-8958. The approved indication is for the treatment of influenza in adults and children.
Cardiac injury leads to significant structural changes in the heart, including enlargement, excess formation of fibrous growth tissue, and abnormalities of the coronary vasculature. While associated factors have been targeted for therapeutic intervention, the results have been conflicting. Most studies have investigated these changes after six days of injury. However, advanced stages of remodeling have already begun by day seven following injury.
The GOP-led push to repeal this long-term care insurance program, which the Obama administration already made clear it would not implement, drew some Democratic votes. During floor speeches, Republican lawmakers cast it as a barrier to achieving a real reform.
› Verified 3 days ago